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Abstract 
The pandemic prevalence of COVID-19 has become a very serious global health issue. Scientists 
all over the world have been heavily invested in the discovery of a drug to combat SARS-CoV-2. 
It has been found that RNA-dependent RNA Polymerase (RdRp) plays a crucial role in SARS-
CoV-2 replication, and thus could be a potential drug target. Here, comprehensive computational 
approaches including drug repurposing and molecular docking were employed to predict an 
effective drug candidate targeting RdRp of SARS-CoV-2. This study revealed that Rifabutin, 
Rifapentine, Fidaxomicin, 7-methyl-guanosine-5'-triphosphate-5'-guanosine and Ivermectin have 
a potential inhibitory interaction with RdRp of SARS-CoV-2, and could be effective drugs for 
COVID-19. In addition, virtual screening of the compounds from ZINC database also allowed 
the prediction of two compounds (ZINC09128258 and ZINC 09883305) with pharmacophore 
features that interact effectively with RdRp of SARS-CoV-2; indicating their potentiality as 
effective inhibitors of the enzyme. Furthermore, ADME analysis along with analysis of toxicity 
was also investigated to check the pharmacokinetics and drug-likeness properties of the two 
compounds. Comparative structural analysis of protein-inhibitor complexes revealed that 
positions of the amino acid Y32, K47, Y122, Y129, H133, N138, D140, T141, S709 and N781 
are crucial for drug surface hotspot in the RdRp of SARS-CoV-2.  
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1. Introduction 
The pandemic Corona Virus Disease 19 (COVID-19) has become a critical, rapidly emerging 
public health issue for the world. It is caused by the outbreak of Severe Acute Respiratory 
Syndrome Corona Virus 2 (SARS-CoV-2), the disease characterized by fever, cough, and severe 
shortness of breathing, nausea, vomiting and diarrhea [1]. As of 10 April 2020, SARS-CoV-2 
infection has been reported in 184 countries with 1,536, 979 confirmed cases and 93,425 total 
deaths [2,3]. Epidemiological data have determined person to person transmission as the route of 
the rapid outbreak of COVID-19, which has become a major obstruction in combating the virus 
[4,5].Clinical studies reported that older patients have a higher case of fatality rate (CFR) than 
the young, and males have a higher CFR than female [6].  Apart from acute respiratory distress, 
COVID-19 patients have been diagnosed with higher rate of renal impairment, indicating the 
development of kidney dysfunction[7]. Unfortunately, there are no proven drugs, vaccines or 
therapies available to fight against COVID -19. 
 
SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus similar to SARS and 
MERS (Middle East Respiratory Syndrome) coronavirus [8]. Along with structural proteins (like 
spike glycoprotein and accessory proteins), the viral genome also encodes non-structural 
proteins, including 3-chymotrypsin-like protease, papain-like protease, helicase and RNA-
dependent RNA polymerase (RdRp)[9]. RdRp is an essential enzyme involved in the replication 
of RNA viruses including SARS-CoV-2. Several anti-viral drugs have been developed targeting 
this enzyme for treating infections like Hepatitis C, Zika and other coronaviruses[10]. Although 
not yet extensively explored, some of these drugs also target the SARS-CoV-2 RdRp or its 
catalyzed polymerization process[11–14].  A recent study suggested that two known anti-viral 
drugs Remdesivir and Favipiravir which are used for the treatment of variety of RNA virus 
diseases, by targeting RNA polymerase and RdRp respectively, could successfully inhibit SARS-
CoV-2 replication in vitro[13–17].Unfortunately, the mechanism of action and the efficacy of 
these compounds remain unclear.  
 
Computation biology and molecular docking approach have a wide variety of applications in 
drug discovery, giving novel insights to the screening of potential drugs for the treatment of 
COVID-19.  These approaches also aid the understanding of the protein-ligand interactions as 
well as in figuring out drug surface hotspot, which are important for the discovery of an effective 
drug[18,19]. In addition, drug repurposing approach is used for the identification of existing 
drugs for one disease, for thetreatment of another disease. As the long-term solution, vaccine, 
will take years to be marketable, effective repurposing of existing drug remains the only 
alternative way to fight against an emerging disease like COVID-19[20–23]. Thus, in the 
presented study, drugs with proven anti-viral activity wereanalyzed using molecular docking and 
pharmacophore modeling technique to target RdRp of SARS-CoV-2. Our findings can open a 
new avenue to fight against COVID-19. 
 
2. Materials and Methods 
2.1 Retrieval of the structure of SARS-CoV-2 RNA Polymerase and Drug Candidates List 
The RdRp structure of SARS-CoV-2 was retrieved from the Protein Data Bank (PDB) with PDB 
ID: 6M71[24]. Furthermore, 44 drug candidates having inhibitory activity against RNA 
polymerase were selected by comprehensive literature study, and their PDB structures were 
retrieved from the Drug Bank Database (Supplementary Table 1) [25]. RdRp inhibitor drugs 
were prioritized; but drugs that are DNA-dependent RNA polymerase inhibitors having the 
antiviral activity were also included. 
 
2.2 Screening of RNA polymerase inhibitors against the RdRp of SARS-CoV-2 
The AutoDock Vina software of molecular docking approaches was employed for the screening 
of the drugs against RdRp of SARS-CoV-2[26]. At first, the crystal structure of RdRp was 
retrieved from the PDB, processed by removing water and complex molecules using 
PyMOL[27]. After preparing the PDB structures of the inhibitors, they were exposed to the 
RdRp polymerase of SARS-CoV-2 for analyzing the lowest binding energy and interactive 
amino acids. The grid box parameters were set to size 80Å x 95Å x 95Å(x, y and z) and centre 
121.253Å x 121.376Å x 120.149Å (x, y and z). The 2D ligand-protein interaction diagrams were 
generated by LigPlot+ to find out the involved amino acids with their interactive position in the 
docked molecule[28]. Discovery Studio and PyMOL were used to visualize and analyze the 
ligand molecules’ interactions with the viral proteins[29]. Additionally, the Protein-Ligand 
Interaction Profiler (PLIP) was also used to analyze the total number of non-covalent interactions 
(hydrogen bonds, water bridges, salt bridges, halogen bonds, hydrophobic interactions, π-
stacking, π-cation interactions and metal complexes) in protein-ligand complexes[30].  
 
2.3 Structural Insights of Drug Surface Hotspot in the RdRp of SARS-CoV-2  
LigPlot+, Discovery Studio and PyMOL were used to figure out the drug surface hotspot from 
the docked structures of RdRp with the top-most polymerase inhibitors. Remdesivir and 
Favipiravir were used as positive control, as they were reported to be effective for COVID-19 by 
several recent studies[13,14]. 
 
2.4 Pharmacophore Modelling and Virtual Screening of ZINC Database  
PharmaGIST was used for the modeling of the pharmacophore features that are essential for the 
interaction of RNA polymerase inhibitors with RdRd of SARS-CoV-2. In this study, the top-
most inhibitors along with Remdisivir were used for the pharmacophore modeling [31,32]. 
ZINCPharmer was used to import the generated pharmacophore from PharmaGISTfor the virtual 
screening of the novel compounds from the ZINC database [33,34]. These novel compounds 
were further used for the screening of new inhibitors of RdRp of SARS-CoV-2. The validity of 
the screened compounds was checked by Molecular docking approaches. 
 
2.5 Drug Likeness Properties Analysis of the Screened Compounds from ZINC Database 
SwissADME server was used to assess the Absorption, Distribution, Metabolism and Excretion 
(ADME) properties of the compounds screened from ZINC database [35]. This server is well 
known for successfully evaluating the pharmacokinetics, drug-likeness and medicinal chemistry 
friendliness of potentialdrug candidates. In this study, the physicochemical parameters (Formula 
Molecular weight, Molar Refractivity, TPSA), lipophilicity (Log Po/w (iLOGP), Log Po/w 
(XLOGP3), Log Po/w (WLOGP), Log Po/w (MLOGP), Log Po/w, (SILICOS-IT), Consensus 
Log Po/w), pharmacokinetic parameters (CYP1A2 inhibitor, CYP2C19 inhibitor, CYP2C9 
inhibitor, CYP2D6 inhibitor, CYP3A4 inhibitor, Log Kp; skin permeation) and water solubility 
(Log S: SILICOS-IT, Solubility) were checked for the screened compounds, also considering all 
default parameters[36,37]. Additionally, OSIRIS Property Explorer and admetSAR were used to 
investigate the undesired effects of these compounds like mutagenicity, tumerogenecity and 
toxicity[38–41]. No ADME or toxicity analysis was required for the top selected drugs since the 
drugs were previously tested for FDA approval. 
 
 
3. RESULTS 
3.1 Screening of RdRp inhibitors against the RdRp of SARS-CoV-2  
Molecular docking of all the RNA polymerase inhibitors against RdRp of SARS-CoV-2 (PDB 
ID: 6M71) revealed Rifabutin, Rifapentine, Fidaxomicin, 7-methyl-guanosine-5'-triphosphate-5'-
guanosineand Ivermectin chronologically as the top-most effective RdRp inhibitorsof SARS-
CoV-2 with highest binding affinity and lowest free energy (Table 1 and Fig. 1). Remarkably, all 
these top listed inhibitors showed lower binding energy compared to the positive control 
Remdesivir and Favipiravir. The whole molecular docking results were included in the 
Supplementary Table 2. 
 
3.2 Structural Insights of Drug Surface Hotspot in the RdRp of SARS-CoV-2 
The molecular docking pattern and involved amino acid residues with their respective position 
were further analyzed to reveal the common interactive sites of RdRp in the SARS-CoV-2. Thus, 
the binding pattern of five most effective compounds along with Remdesivir and Favipiravir, 
were analyzed to observe the common drug surface hotspot. It was found that the amino acid 
Y32, K47, Y129, H133, N138, C139, T141 and S709 in RdRp were involved in the interaction 
with Rifabutin. The amino acid position of Y32, K47, Y129, H133 and S709 along with D140 
and N781 were also found crucial for the RdRp of SARS-CoV-2 to interact with Rifapentine, 
Fidaxomicin, 7-methyl-guanosine-5'-triphosphate-5'-guanosine and Ivermectin (Table 1 and Fig. 
2& 3). Most surprisingly, these amino acid residues were also found to be involved in the 
interaction of Remdesivir (K47, Y129, A130, H133, F134, D135, N138, C139, T141, S709, 
T710, D711, Q773 and N781) and Favipiravir (Y129, H133, S709, K780 and N781).  
 
 
3.3 Pharmacophore Modeling and Screening of ZINC Database 
The top listed RdRp inhibitors along with Remdesivir were further used for the pharmacophore 
modeling and screening of ZINC database. The pharmacophore modeling (predicted by the 
PharmaGIST) revealed6 spatial features (Aromatic-1, Hydrophobic-1 and Acceptors-4) (Figure 
3). This pharmacophore model was imported in the ZINCPharmer for the screening of the ZINC 
Database, which revealed four different hits (ZINC09128258, ZINC09883305, ZINC09883308 
and ZINC11286235). In addition,molecular docking analysis revealed two compounds 
(ZINC09128258 and ZINC09883305) that could also act as the inhibitors of RdRp of SARS-
CoV-2 as they showed similar binding pattern as the top drugs and controls (Table 2 and Fig. 5 
& 6). However, these two compounds showed lower binding affinity than the top selected RdRp 
inhibitors. Additionally, higher number of non-covalent interactions was found for 
ZINC09883305 (9 non-covalent interactions). 
 
3.4 Drug Likeness Properties Analysis of the Screened Compounds from ZINC 15 
Database 
The physico-chemistry, pharmacokinetics, medicinal chemistry friendliness and toxicity of these 
two screened compounds (ZINC09128258 and ZINC09883305) from ZINC database were 
analyzed by SwissADME, ADMETsar and OSIRIS Property Explorer. The physiochemical 
parameters, lipophilicity and water solubility of these compounds are described in Table 3. 
Water solubility was also studied in this study and found that all the compounds were moderately 
soluble. Other important properties such as Molecular weight (MW), molecular refractivity (MR) 
and topological polar surface area (TPSA), which are very useful for the estimation of ADME 
properties were also included in this study. Remarkably, none of the screened compounds 
showed any undesired effects such as mutagenicity, tumorigenicity, irritating and reproductive 
effects. However, these compounds showed CYP450 enzymes inhibition effects except 
CYP1A2. Lastly, BOILED-Egg model was employed to calculate the Blood-brain barrier (BBB) 
permeation that revealed no BBB permeate in the studied compounds[42]. 
 
4. Discussion 
At present, COVID-19 isa global challenge for the scientific communities as its pandemic 
attitude is dangerously affecting millions of people and taking thousands of lives everyday. But 
to date, no satisfactory breakthrough has been made in the treatment of Covid-19[43–46]. 
Several attempts have been made to treat this disease but these drug candidates remain 
questionable owing to low efficacy[47]. Computational approaches along with drug repurposing 
methods could be an effective approach to this COVID-19 challenge. In this study, several 
polymerase inhibitors targeting RdRp of SARS-CoV-19were studied, as RdRp had already 
shown to be an effective anti-viral drug target for various viral pathogens such as Hepatitis C 
Virus, HIV, Zika virus etc[48,49]. Here, drug repurposing along with molecular docking was 
employed for the screening and analysis of the drug candidates against RdRp of SARS-CoV-2. 
Moreover, the common drug surface hotspot was studied along with modeling of pharmacophore 
which is very important for drug discovery.  Additionally, novel compounds from ZINC 
database were screened out which could be developed as a new drug to treat COVID-19.  
 
RdRp plays indispensable roles in the life cycle of RNA viruses. RNA viruses initiate RNA 
synthesis by virus polymerase utilizing primer-independent and primer-dependent mechanism. 
Moreover, RdRp based RNA synthesis doesn’t occur in the mammalian cells offering an 
opportunity to design drugs specifically acting against RNA viruses. Additionally, the protein 
structure of RdRp in RNA viruses is found to be remarkably conserved. Various antiviral drugs 
have been developed targeting this enzyme for the treatment of infections caused by RNA 
viruses and they are working effectively[10,50].Therefore, this present study aimed to identify 
potential drugs targeting this enzyme for the treatment of COVID-19. 
 
Molecular docking analysis revealed that Rifabutin, Rifapentine, Fidaxomicin, 7-methyl-
guanosine-5'-triphosphate-5'-guanosine and Ivermectin could be potential RdRp inhibitors of 
SARS-CoV-2. Notably, Ivermectin has already been reported as showing inhibitor property in 
SARS-CoV-19 replications in vitro[51]. Rifabutin and Rifabutin have also been reported for 
their anti-viral activity against HIV and vaccinia virus respectively[52,53]. Moreover, the vast 
number of non-covalent interactions between these screened compounds with RdPd suggests that 
the protein-inhibitor complexes are very stable. In addition to these drugs, Remdesivir along with 
Favipiravir which has already been suggested for the treatment of COVID-19, was also found to 
be effective as the inhibitor of RdRp of SARS- CoV-2[14]. Although their binding affinity was 
lower than the aforementioned top five drugs, the binding pattern was almost similar to these 
drugs.The drug surface hotspot study revealed that the molecular binding sites of all the five 
compounds were of a similar pattern that could be the hotspot of drug binding to the RdRp of 
SARS-CoV-2. This study suggested that amino acids Y32, K47, Y122, Y129, H133, N138, 
D140, T141, S709 and N781 in RdRp of SARS-CoV-2 could make effective interactions with 
drugs, though this needs to be validated in wet lab. Additionally, pharmacophore was designed 
using the top RdRp inhibitor drugs along with Remdesivir, which was used further for the 
screening of ZINC database. Molecular docking analysis revealed that two compounds among 
the four hits had interacted effectively with the RdRp of SARS-CoV-2 which is indicativeof their 
potential as inhibitors of the enzyme. Although their binding affinity was lower than one control 
(Remdesivir), the vast number of interactions would give the complex its stability with this 
binding energy. Moreover, ADME and toxicity analysis of these compounds suggested that they 
could be used for the development of new drugs to treat COVID-19. However, the study of 
cytochromes P450 (CYP) isoforms inhibition concluded that there was a possibility that the 
suggested compounds could interact with CYP isoforms.  
 
5. Conclusion 
COVID-19 has created a disastrous global crisis affecting thousands of people every day, having 
already claimed thousands of lives, and severely hampered the global economy. The present 
study aimed to combat this global crisis by suggesting potential drug candidates for the treatment 
of COVID-19. Rifabutin, Rifapentine, Fidaxomicin, 7-methyl-guanosine-5'-triphosphate-5'-
guanosine, Ivermectin and other screened novel compounds made the common drug surface 
hotspot in the RdRp of SARS-CoV-2, highly suggesting that they could be effective in the 
treatment of SARS-CoV-2. 
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Tables 
Table 1: Top 5 RdRp Inhibitors with Binding Energy and Involved Amino Acid with Position 
Sl. No. Drug Bank 
ID 
Name Binding 
Energy 
(kcal/mol) 
No of Non-
Covalent 
Interactions 
Involved Amino Acids 
with positions 
1 DB00615 Rifabutin -11.8 7 Y32, K47, Y129, H133, 
N138, C139, T141, 
S709 
2 DB01201 Rifapentine -11.6 10 V31, Y32, R33,K47,  
K121, Y122, Y129, 
H133, N138, C139, 
D140,  T141, S709, 
N781 
3 DB08874 Fidaxomicin -10.9 16 Y32, K47, Y129, N131, 
H133, N138, D140, 
T141, S709, T710, 
D711, K714, N781, 
Q773 
4 DB03958 7-methyl-
guanosine-5'-
triphosphate-
5'-guanosine 
-10 12 Y32, R33, K47,Y122, 
Y129, H133, D140, 
T141, A706, S709, 
T710, D711, , G774, 
N781 
5 DB00602 Ivermectin -9.9 9 Y32, L49, Y129, H133, 
S709, T710, K714, 
G774, N781 
Control  DB14761 Remdesivir -8.8 5 K47, Y129, A130, 
H133, F134, D135, 
N138, C139, T141, 
S709, T710, D711, 
Q773 and N781 
Control DB12466 Favipiravir -5.3 6 Y129, H133, S709, 
K780 and N781 
 
 
 
 
Table 2: Screened Compounds Molecular docking Result with involved amino acid 
Sl. No. ZINC ID Compound 
IUPAC Name 
Binding 
Energy 
kcal/mol 
No. of Non-
covalent 
Interactions 
Involved 
Amino Acids 
1 ZINC09128258 [(1,1-dioxo-1λ⁶-
thiolan-3-yl)(2-
methylpropyl)carba
moyl]methyl 3-
(furan-2-amido)-4-
methylbenzoate 
-7.1 6 Y32, K47, 
H133, D135, 
A706, S709, 
T710. D711, 
K714, G774, 
N781, S784 
2 ZINC09883305 [(butan-2-yl)(1,1-
dioxo-1λ⁶-thiolan-
3-
yl)carbamoyl]meth
yl 3-(furan-2-
amido)-4-
methylbenzoate 
-7 9 Y129, H133, 
D135, N138, 
A706, S709, 
T710, K780, 
N781, S784 
Control Drug Bank ID: 
DB14761 
Drug Name: 
Remdesivir 
-8.8 5 K47, Y129, 
A130, H133, 
F134, D135, 
N138, C139, 
T141, S709, 
T710, D711, 
Q773 and 
N781 
Control Drug Bank ID: 
DB12466 
Drug Name: 
Favipiravir 
-5.3 6 Y129, H133, 
S709, K780 
and N781 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Drug Likeness Properties analysis of Screened compounds from ZINC 15 Database 
 
Drug Likeness Properties ZINC09128258 ZINC09883305 
Formula C23H28N2O7S C23H28N2O7S 
Molecular Weight (g/mol) 476.54 476.54 
Molar Refractivity 122.38 122.38 
TPSA (Topological Polar Surface Area) 131.37 131.37 
Lipophilicity 
Log Po/w (iLOGP) 3.15 3.01 
Log Po/w (XLOGP3) 2.8 2.8 
Log Po/w (WLOGP) 3.56 3.7 
Log Po/w (MLOGP) 1.28 1.28 
Log Po/w (SILICOSNoIT) 2.62 2.62 
Consensus Log Po/w 2.68 2.68 
Solubility 
LOG S (SILICOS-IT) -5.77 -5.77 
SILICOS-IT Solubility (mg/ml) 8.02E-04 8.02E-04 
SILICOS-IT Solubility (mol/l) 1.68E-06 1.68E-06 
Solubility class Moderately soluble Moderately soluble 
Pharmacokinetics 
Druglikeness -3.39 1.84 
Drug-score 0.34 0.6 
Blood-Brain-Barrier 
Permeant 
No No 
Human Intestinal Absorption Yes Yes 
Caco-2 Permeant No No 
P-glycoprotein Substrate No Yes 
CYP450 1A2 Inhibitor No No 
CYP450 2C9 Inhibitor Yes Yes 
CYP450 2D6 Inhibitor Yes Yes 
CYP450 2C19 Inhibitor Yes Yes 
CYP450 3A4 Inhibitor Yes Yes 
CYP Inhibitory Promiscuity Yes Yes 
Toxicity 
AMES Toxicity No No 
Carcinogens No No 
Biodegradation No No 
Acute Oral Toxicity (kg/mol) III, 2.787 III, 2.731 
Mutagenicity No No 
Tumorigenicity No No 
Irritating effects No No 
Reproductive effects No No 
Figure legends 
Fig. 1: Docked figures of Top 5 drug candidates with RdRp of SARS-CoV-2 
 
Fig. 2: The interaction of RdRp with (a) Rifabutin (b) Rifapentine (c) Fidaxomicin (d) 7-methyl-
guanosine-5'-triphosphate-5'-guanosine and (e) Ivermectin. Here,Drugs are in orange while 
protein active site pockets are in cyan lines. Solid blue lines represent H-bonds, while 
hydrophobic interactions are gray dashed lines. In addition, salt bridges, π-cation stacking, and 
halogen contacts are represented by yellow spheres connected by black dashed lines, orange 
dashed lines, and cyan lines, respectively. 
 
Fig. 3: Structural Analysis of Drug Hotspot in RdRp of SARS-CoV-2 
 
Fig. 4: Ligand-based pharmacophore model of RdRp of SARS-CoV-2. Here, green represents 
the hydrophobic features, violet represents aromatic features and yellow represents the hydrogen 
acceptor features.  
 
Fig. 5: Docked figures of selected ZINC compounds with RdRp of SARS-CoV-2. 
 
Fig. 6: The interaction of RdRp with (a) ZINC09128258 and (b) ZINC09883305. Here, Drugs 
are in orange while protein active site pockets are in cyan lines. Solid blue lines represent H-
bonds, while hydrophobic interactions are gray dashed lines. In addition, salt bridges, π-cation 
stacking, and halogen contacts are represented by yellow spheres connected by black dashed 
lines, orange dashed lines, and cyan lines, respectively.
 
  
 
  
 
 
